ANSO LABS
Free tool

PRISM risk score.

Enter age, sex, karyotype and mutations. See the PRISM-3 risk group (Low, Moderate or High) for newly diagnosed AML treated with a hypomethylating agent plus venetoclax, and exactly how the score is built.

For healthcare professionalsRuns in your browserNothing stored or sent
Try an example profile
Age and sex
The score is defined for ages 18 to 100.
Sex at birth
Karyotype

Cytogenetic risk, by karyotype or FISH.

Which abnormalities are ELN 2022 adverse?

t(6;9)(p23.3;q34.1) DEK::NUP214; t(v;11q23.3) KMT2A-rearranged; t(9;22)(q34.1;q11.2) BCR::ABL1; t(8;16)(p11.2;p13.3) KAT6A::CREBBP; inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) GATA2, MECOM(EVI1); t(3q26.2;v) MECOM(EVI1)-rearranged; −5 or del(5q); −7; −17/abn(17p); complex karyotype; monosomal karyotype. The ELN tool gives each definition.

Gene mutations

Tick each gene reported as mutated. Anything unticked is scored as not mutated. Colour shows which way a gene moves the score: rose raises it, green lowers it.

Clinical
For the 4-gene group only

Lachowiez et al., J Clin Oncol 2026. An independent implementation; the authors’ own calculator is at prism-aml.com.

How it works

  • Enter age, sex at birth and karyotype, then tick every gene reported as mutated. Anything unticked is scored as not mutated.
  • The PRISM score is a sum: a weight for each finding, added to a weight for each year of age. There is no intercept. “How the score is built” lists every term, biggest first.
  • The PRISM-3 group compares the score with two cut points: Low is below 1.0988, Moderate is from there to below 1.6132, High is 1.6132 or more.
  • “Decisive findings” shows which findings the group hinges on. Click one to see what happens without it.
  • The 4-gene group is a separate, simpler grouping shown beside it: TP53 mutated is Adverse; otherwise FLT3-ITD, KRAS or NRAS mutated is Intermediate; otherwise Favorable.
  • Your entries stay in your browser. A shared link keeps them after the # in the address, which browsers do not send to servers.

Source and limits

  • Implements the PRISM model of Lachowiez et al., J Clin Oncol 2026;44(25):2422–2434. An independent implementation, not affiliated with or endorsed by the authors. If this page and their calculator ever disagree, trust theirs.
  • The coefficients, cut points and input ranges are those of the authors’ online calculator. This page was checked against it on 22 October 2026: identical scores on more than 20,000 inputs, including values either side of each cut point.
  • For adults aged 18 to 100 with newly diagnosed AML treated with a hypomethylating agent plus venetoclax. It gives a risk group, not a survival estimate or a treatment recommendation.
  • A reference tool for healthcare professionals. It does not diagnose, recommend treatment, or replace clinical judgment. Do not enter patient identifiers; none are needed.